Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00095290 · ClinicalTrials.gov registry record · Phase 4

Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria

A Phase 4 study, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 4
Development phase
400
Enrollment target

NCT00095290: Completed Phase 4 study, sponsored by Bristol-Myers Squibb.

NCT00095290 is a Phase 4 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 400 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00095290, a Phase 4 study, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 4
Development phase
400 participants
Enrollment target

Study Summary

Albumin in the urine is usually a signal that you might be at risk of cardiovascular complications. The purpose of this study is to determine if the albumin in your urine can be decreased by the treatment regimen that consists of irbesartan taken at the same time with ramipril.

Interventions

  • DRUG Ramipril + Irbesartan
  • DRUG Ramipril + Placebo

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2004-09
Est. Completion 2005-11
Phase Phase 4
Bristol-Myers Squibb

1,025 total trials

What the finished NCT00095290 record still lists

NCT00095290 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (23% lower).

The record links to 0 conditions, and to 2 interventions - of which Ramipril + Irbesartan is the first listed.

NCT00095290 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00095290 about?

NCT00095290 is a clinical study titled "Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria". Albumin in the urine is usually a signal that you might be at risk of cardiovascular complications. The purpose of this study is to determine if the albumin in your urine can be decreased by the treatment regimen that consists of irbesartan taken at the same time with ramipril.

What is the current status of trial NCT00095290?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 400 participants. The study started on 2004-09. Estimated completion is 2005-11.

What interventions are being tested in trial NCT00095290?

The interventions under investigation include: Ramipril + Irbesartan (DRUG), Ramipril + Placebo (DRUG).

Who is sponsoring clinical trial NCT00095290?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00095290's enrollment target sits among peer trials

400 211th of 2000 higher than 1,784 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00095290, the US trial registry maintained by the National Library of Medicine. NCT00095290 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.